MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

Tenofovir exalidex

產品活性：Tenofovir exalidex (CMX157) 是一種非環核苷酸類似物 Tenofovir 的脂質結合物，對野生型和抗逆轉錄病毒耐藥的 HIV 毒株，包括多藥核苷/核苷酸類似物耐藥病毒，都有活性。Tenofovir exalidex 對人外周血單個核細胞中所有主要的HIV-1和HIV-2亞型以及單核細胞來源的巨噬細胞中所有 HIV-1 菌株具有活性，EC₅₀ 范圍在 0.2 和 7.2 nM 之間。Tenofovir exalidex 具有口服活性，無明顯毒性。Tenofovir exalidex 對 HBV 也有活性。

研究領域：Anti-infection  |  Cell Cycle/DNA Damage

作用靶點：HIV  |  HBV  |  Nucleoside Antimetabolite/Analog

In Vitro: Tenofovir exalidex is consistently >300-fold more active than Tenofovir against multiple viruses in several different cell systems. Tenofovir exalidex will be effective against MNR mutants, including those that are unresponsive to all currently available NRTIs. Notably, the average EC₅₀ in PBMCs for CMX157 against a panel of 27 wild-type HIV-1 isolates representing group M subtypes A to G and group O was 2.6 nM (range, 0.2 to 7.2 nM).
Tenofovir exalidex exerts its therapeutic actions by inhibiting HBV polymerase-mediated HBV DNA elongation, but there is no known binding of cyclophilins to HBV polymerase nor participation of cyclophilins in DNA elongation. The combinational effect of CRV431 (host-targeting) and Tenofovir exalidex (direct-acting) on HBV DNA production is more consistent with the two compounds acting on distinct steps of the HBV life cycle.

In Vivo: Tenofovir exalidex (Sprague-Dawley rats) is orally available and has no apparent toxicity when given orally to rats for 7 days at doses of 10, 30, or 100 mg/kg/day.Tenofovir exalidex (5-10 mg/kg; oral gavage; daily for a period of 16 days) decreases liver HBV DNA levels dose-dependently.

相關產品：2’-dG (iBu)-2’-phosphoramidite  |  Peldesine dihydrochloride  |  3’-Beta-C-Methyl-N6-(m-trifluoromethylbenzyl)adenosine  |  IBU-DC Phosphoramidite  |  8-Methylguanosine  |  Abacavir sulfate  |  2'-Deoxy-8-methylamino-adenosine  |  N6-Isopentenyl-2’-deoxy adenosine, 2’-deoxy riboprine  |  HIV-IN-6  |  7-Ethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine  |  Epicoccone B  |  5’-Deoxy-5’-N-methylaminothymidine  |  N-Acetyl-2′-deoxycytidine  |  5-Carboxymethylaminomethyluridine  |  3-Deoxy-1,2-O-isopropylidene-5-p-toluoyl-a-D-glycero-pent-3-enofuranose  |  3,5-Di-O-benzoyl-2-deoxy-2-fluoro-5-trifluoromethyl-arabinouridine  |  Ditiocarb  |  6-Mercaptopurine-¹³C₂,¹⁵N  |  4′,5′-Didehydro-5′-deoxyadenosine  |  2’,3’,5’-Tri-O-acetyl-5,N3-dimethyluridine  |  2’-Deoxy-2’-fluoro-N1-methyluridine  |  5'-Homocytidine  |  2'-Deoxypseudoisocytidine  |  3’-O-DMT-N2-isobutyryl-2’-O-(2-methoxyethyl)guanosine  |  5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)-5-methyluridine  |  Nevirapine  |  DAPTA  |  Aloperine  |  Elipovimab  |  3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-5-methyl-β-D-arabino-uridine

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領；
•   產品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產品，廣泛應用于新藥研發、生命科學等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學分析檢測分析，藥物篩選等專業技術服務；
•   設有專業的實驗中心和嚴格的質控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告，確保產品的高純度、高品質；
•   產品的生物活性多經各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業團隊跟蹤新的制藥及生命科學研究進展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機構建立了長期的合作。